
BioHarvest Sciences Inc.'s (OTCPK: CNVCF) (CSE:BHSC) (FSE:8MV) sales of its flagship VINIA product in Q1 2022 reached $787K, representing 112% growth compared to the same quarter of last year.
BioHarvest also had a strong quarter in R&D execution, highlighted by a March 23 declaration of successful completion of its cannabis R&D program with the production of cannabis biomass in large-scale industrial bioreactors - signaling the start of commercialization of the cannabis product. BioHarvest is in the process of transitioning the current R&D license to a production license.